Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print 3-drug combination 'extremely promising' as first-line therapy for multiple myeloma

3-drug combination 'extremely promising' as first-line therapy for multiple myeloma

December 12, 2007

ATLANTA-A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

The three-pronged regimen of Velcade, lenalidomide (Revlimid) and dexamethasone - referred to as Rev/Vel/Dex - has achieved an overall response rate of 98 percent in 42 patients evaluated thus far in a Phase 1-2 trial, said Paul Richardson, MD, of Dana-Farber and the study's principal investigator. He added that 52 percent of the patients had high quality responses (very good partial response or better), with 30 percent achieving complete response to date.




"These may be some of the best response rates we've seen to date with up-front therapies, and although these are preliminary results, they are extremely promising," Richardson said. The patients were previously untreated when they received the Rev/Vel/Dex combination.

Velcade is a "smart" drug known as a proteasome inhibitor that blocks the myeloma cells' waste disposal system, creating an accumulation of toxic compounds that poison the cell. Revlimid is a chemical relative of thalidomide that affects several pathways in cancer cells, including immune mechanisms and blood vessel growth to tumors. Dexamethasone is a steroid hormone that counters inflammation and is used to treat hematologic malignancies such as myeloma. Studies leading to the trial of the three drugs in combination were carried out at Dana-Farber.

While these are the first results from trials of Rev/Vel/Dex given as initial, first-line therapy for the blood cancer, the combination has already been shown effective for multiple myeloma patients who had relapsed following successful treatment or who had not responded to standard therapies.

Richardson also reported at the ASH meeting preliminary data from a Dana-Farber led multicenter Phase 2 trial of the combination in relapsed or refractory myeloma. "These data confirm the favorable side effect profile," said Richardson, "and the response rate of 72 percent - including complete, partial, and minor responses - is very encouraging."

The responses, he added, appear to be holding up well, with a duration of more than one year for some patients to date. Both trials will continue to enroll patients, and final results are expected next year.

Dana-Farber Cancer Institute



Related Multiple Myeloma News Articles Multiple Myeloma News and Current Multiple Myeloma Events RSS Multiple Myeloma News and Current Multiple Myeloma Events RSS
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.

Clinical study shows biological and clinical activity in relapsed leukemia patients
Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).

Immune system pathway identified to fight allergens, asthma
For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction.

U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher.

Experimental procedure induces tolerance to mismatched kidney transplants
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.

Stem cells make bone marrow cancer resistant to treatment
Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.

Researchers Uncover Key Trigger for Potent Cancer-Fighting Marine Product
An unexpected discovery in marine biomedical laboratories at Scripps Institution of Oceanography at UC San Diego has led to new, key information about the fundamental biological processes inside a marine organism that creates a natural product currently being tested to treat cancer in humans. The finding could lead to new applications of the natural product in treating human diseases.

Novel anticancer strategy moves from laboratory to clinic
Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

Oral osteoporosis meds appear to reduce the risk of jaw degradation
Athanasios Zavras began receiving messages from distraught patients in 2005 after case reports linked oral osteoporosis meds to bone death in the jaw.

ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.
More Multiple Myeloma News Articles


100 Questions and Answers About Myeloma (100 Questions & Answers about . . .) (100 Questions & Answers about . . .)
by Asad Bashey

Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a...



Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J. Heller

A concise and helpful overview of the disease, including therapies, medications, problems, and lifestyle changes. Many helpful hints in an easy to understand format which avoids a lot of hard to understand terminology in favor of a more light-hearted approach. Includes reproducible forms and many references to other...



Myeloma (The Biology of Cancer)
by Jerome E., Ph.d. Tanner



Multiple Myelomas, An Issue of Hematology / Oncology Clinics (The Clinics: Internal Medicine)
by Kenneth C. Anderson

Although treatable with conventional and high dose therapies, multiple myeloma (MM) remains incurable. However, recent advances in oncogenomics, coupled with increased understanding of the role of the bone marrow (BM) microenvironment in MM pathogenesis, has provided the basis for a new treatment paradigm targeting the tumor cell in the BM milieu to overcome conventional drug resistance and...



Multiple Myeloma and Related Plasma Cell Disorders (Hematologic Malignancies)

Building on the considerable expertise of the dysproteinemia unit at Mayo Clinic, this book spans the gamut from multiple myeloma, the most frequent and most serious of the monoclonal gammopathies, to the rarest related disorders. Laboratory evaluation, associations with nonhematologic disorders, monoclonal gammopathies of undetermined significance, the more obscure plasma cell dyscrasias,...

Myeloma Therapy:: Pursuing the Plasma Cell (Contemporary Hematology)

Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all...

Multiple Myeloma (State of the Art Series)

Multiple myeloma, typically characterized by the accumulation of clonal plasma cells in multiple sites of the bone marrow, is the second most common hematologic malignancy with an incidence of 15,000 patients per year in the United States and a prevalence of approximately 50,000. Although the majority of patients respond to initial treatment with chemotherapy and radiation, most...



Hematopoietic Stem Cell Transplantation, Second Edition (Contemporary Hematology)



Carpe Diem: Enjoying Every Day with a Terminal Illness
by Ed Madden

A heartwarming book about living with a terminal illness and making every day...



Biology and Management of Multiple Myeloma (Current Clinical Oncology) (Current Clinical Oncology)

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and...

© 2008 BrightSurf.com